DR. HERMAN J. EDELING

NEUROSURGEON / MEDICO-LEGAL PRACTITIONER / MEDIATOR

M.B.,B.Ch.(Wits): F.C.S.(S.A.)(Neuro): HPCSA Reg No: MP 180408: PR 2401002

Telephone : 011-648-5101 Gauteng - Republic of South Africa **Email : edeling@emlct.com**

THE GOOD NEWS about COVID-19 July 2021

The pathophysiology of COVID-19 has been studied and understood by scientists around the world. This understanding has enabled the development, months ago, of safe and effective means of preventing and treating COVID-19.

The GOOD NEWS is that there is now an abundance of scientific evidence for <u>safe</u>, <u>effective and cheap prevention</u> of COVID-19. The further GOOD NEWS is that there is an abundance of scientific evidence for <u>safe and effective home-based treatment</u> of COVID-19 in the distinctly different phases of the disease. You have more control than you may have been led to believe.

We believe, in the circumstances of a global pandemic, that:

Every human being has the right to know this GOOD NEWS.

Every health care practitioner has an ethical duty to familiarize themselves with the abundant EMERGING SCIENTIFIC EVIDENCE, and to adopt a proper scientific approach in informing, advising and treating their patients.

Every government that cares for the health and well-being of its people should spread the GOOD NEWS to allay mass anxiety and panic, and should implement rational mass distribution of safe, effective and cheap nutraceuticals and/or pharmaceuticals that have been proven to reduce population incidences of COVID-19.

For ease and rapidity of understanding, the principles of the GOOD NEWS are summarized below in brief format, and are supplemented by reference to multiple scientific publications. Dedicated medical scientists have already published a wide array of COVID-19 prevention and treatment recommendations. This document does not constitute medical advice by the author – it serves merely as a brief explanatory overview, as well as a convenient introduction providing access to useful publications.

COVID-19 Stage 0: Prevention of disease for asymptomatic individuals

(References: 1 2 3 7 8 9 12 14 16 19 20 21 22)

Immune support: Nutraceuticals, in particular Vitamin D3, Zinc, Vitamin C, Quercetin and

Melatonin.

Anti-infective agent: Ivermectin.

GOOD NEWS: The majority of individuals on this regimen will remain in good health, and will not

progress to Stage 1. This regimen should be particularly recommended for high risk individuals,

i.e. over 50 years of age and/or with comorbidities. Younger healthy individuals may or may not

elect to protect themselves.

COVID-19 Stage 1: First 5 days of illness – viral proliferation: Early home-based treatment for

patients with symptoms of the disease

(References: 4 5 6 7 8 9 10 11 12 14 16 18 22)

Immune support: Increased dosage of above nutraceuticals.

Anti-infective agents ≥2: Ivermectin [increased dosage] or Hydroxychloroquine, together with

antibiotics such as Azithromycin, Doxycycline or Clindamycin.

GOOD NEWS: The majority of individuals on this regimen will recover from the illness, and will not

progress to Stage 2.

COVID-19 Stage 2: ≥ Day 5 Secondary phase of illness - inflammo-thrombotic response:

Advanced home-based treatment for patients with secondary onset or escalation of symptoms.

(References: 4 5 6 7 8 9 10 11 12 15 18 22 23)

Immune support: Continue as above.

<u>Anti-infective agents ≥2</u>: Continue as above.

<u>Immunomodulators</u>: Corticosteroids such as Budesonide (Pulmicort) nebulization, oral Dexamethasone or oral Prednisone.

Anti-inflammatory agents: Colchicine.

Anti-histamines: Promethazine (Phenergan) and Cimetidine (Tagamet).

Anti-leukotrienes: Montelukast (Singulair).

Antiplatelet and antithrombotic agents: Aspirin. Enoxaparin (Clexane) or Rivaroxaban (Xarelto).

<u>Non-invasive respiratory support</u>: Home oxygen. Home CPAP (continuous positive airways pressure).

GOOD NEWS: The majority of individuals on this regimen will recover from the illness, and will not progress to Stage 3 or require admission to hospital. Telemedicine allows these treatments at home to be properly monitored and supervised by suitably informed medical practitioners.

COVID-19 Stage 3: Late and severe phase of illness – respiratory distress and thrombosis: Specialist treatment in hospital and/or ICU

The unfortunate minority of individuals who progress to severe COVID-19, with respiratory distress and systemic thromboembolism, require individualized treatment in hospital and/or ICU, under the care of a specialist physician. Details of hospital and ICU treatment, which include the above as well as interventions such as high flow oxygen, CPAP, intubation and mechanical ventilation, are not included in this document and are deferred to suitably knowledgeable specialists.

GOOD NEWS: Even without the above measures in Stages 0, 1 and 2, the majority of the population will not develop the late and severe Stage 3 of the disease. With the above prevention

and treatment, a greater majority, even of high risk individuals, will not develop the late and severe Stage 3 of the disease. With early ambulatory multidrug therapy in high-risk patients (age > 50 with ≥1 comorbidity) Procter et al found an 87.6% reduction in hospitalizations and a 74.9% reduction in deaths. ⁴

REFERENCES:

- COVID-19 is a lack of nutrients, exploited by a virus Huber https://www.primarydoctor.org/covid-19-is-a-lack-of-nutrients
- Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity Mercola https://www.researchgate.net/publication/345079485_Evidence_Regarding_Vitamin_D_and_R
 isk of COVID-19 and Its Severity
- 3. World Health Organization Model List of Essential Medicines = 21st List 2019 https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06
- Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19) - Procter et al -https://ijirms.in/index.php/ijirms/article/view/1100/822
- SARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermath McCullough & Vijay https://rcm.imrpress.com/EN/10.31083/j.rcm.2021.01.301
- Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) – McCullough et al https://rcm.imrpress.com/article/2020/2153-8174/RCM2020264.shtml
- 7. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 Kory et al
 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

- Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Metaanalysis, and Trial Sequential Analysis to Inform Clinical Guidelines – Bryant et al -https://journals.lww.com/americantherapeutics/Fulltext/2021/08000/lvermectin_for_Prevention_and_Treatment_of.7.aspx
- The BIRD (British Ivermectin Recommendation Development) Recommendation on the Use of Ivermectin for Covid-19 - https://bird-group.org/wp-content/uploads/2021/03/BIRD-proceedings-02-03-2021_v1.5.1.pdf
- 10. A Guide to Home-Based COVID Treatment Step-By-Step Doctors' Plan That Could Save Your Life - Orient & Vliet - Association of American Physicians and Surgeons https://aapsonline.org/CovidPatientTreatmentGuide.pdf
- 11.C19 Protocols Reducing Risk of COVID-19 Infection and Severity Early Treatment Protocols https://c19protocols.com/
- 12. Online Database of Ivermectin COVID-19 studies 101 studies, 67 peer reviewed, 60 with results comparing treatment and control groups https://c19ivermectin.com/
- 13. Online Database of HCQ COVID-19 studies 317 studies, 236 peer reviewed, 265 comparing treatment and control groups https://c19hcq.com/
- 14.FLCCC (Front Line COVID-19 Critical Care Alliance) I-MASK+ Prevention & Early Outpatient
 Treatment Protocol For COVID-19 https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf
- 15.FLCCC MATH+ Hospital Treatment Protocol For COVID-19 https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf

- 16.FLCCC I-MASS Prevention & At Home Treatment Mass Distribution Protocol for COVID-19 https://covid19criticalcare.com/wp-content/uploads/2021/06/FLCCC-I-MASS-Protocol.pdf
- 17.FLCCC I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS) https://covid19criticalcare.com/wp-content/uploads/2021/06/FLCCC-Alliance-I-RECOVER-Management-Protocol-for-Long-Haul-COVID-19-Syndrome.pdf
- 18.FLCCC Complete Guide to the Care of the COVID-19 patient
 https://covid19criticalcare.com/wp-content/uploads/2020/12/FLCCC-Protocols-%E2%80%93-A-Guide-to-the-Management-of-COVID-19.pdf
- 19.Why COVID-19 is not so spread in Africa: How does Ivermectin affect it? Tanioka https://www.researchgate.net/publication/350425421_Why_COVID-
 19 is not so spread in Africa How does Ivermectin affect it
- 20. Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers Behera et al https://assets.researchsquare.com/files/rs-208785/v1/d6ff79a3-d354-4aba-a6b0-4bc123bbd225.pdf?c=1613410891
- 21. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 Rajter et al https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/pdf/main.pdf
- 22. Treatments to Consider Based Upon the Best Available Evidence Research Results.

 Proposed Treatment Approaches for Prophylaxis, SARS-COV-2, COVID-19, and Post-Vaccination; For You To Discuss With Your Physician Fleming https://21a86421-c3e0-461b-83c2-cfe4628dfadc.filesusr.com/ugd/659775_409b4bb7107f4320be075ce1404b048d.pdf
- 23. Dr Chetty's 8th Day Therapy For COVID-19 https://emlct.com/wp-

content/uploads/2021/08/COVID-Rx-4-DR-CHETTY-8th_day_therapy_may_12_2021.pdf

24. COVID-19 – Blind Faith or Open Minds - Critical Thinking in Times of Crisis - HJ Edeling - https://emlct.com/wp-content/uploads/2021/08/COVID-19-BlindFaithOrOpenMinds-LH.pdf

Terman J. Edeling.

22 July 2021